Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio

Multimodality therapy is the current standard of care for resectable stage III non-small cell lung cancer (NSCLC). Approximately 10% of all NSCLC cases present as stage IIIA-N2, and for these individuals, disease control and overall survival (OS) remain poor, with 5-year survival rates of 23% [1]. Based on randomized trials and a meta-analysis demonstrating improved OS with the addition of induction chemotherapy (CT) plus surgery versus surgery alone, induction chemotherapy is a reasonable option for resectable stage IIIA-N2 NSCLC [2,3].

Source: Lung Cancer - May 18, 2019 Category: Cancer & Oncology Authors: Ashwin Shinde, Zachary D. Horne, Richard Li, Scott Glaser, Erminia Massarelli, Marianna Koczywas, Loretta Erhunmwunsee, Karen L. Reckamp, Benny Weksler, Ravi Salgia, Sushil Beriwal, Arya Amini Source Type: research